Researcher
Johan Maertens
- Disciplines:Biochemistry and metabolism, Microbiology, Systems biology, Laboratory medicine, Medical biochemistry and metabolism
Affiliations
- Laboratory of Clinical Microbiology (Division)
Member
From1 Oct 2014 → Today - Department of Microbiology, Immunology and Transplantation (Department)
Member
From1 Oct 2013 → 30 Sep 2014 - Woman and Child (Division)
Member
From1 Apr 2013 → 30 Sep 2013
Projects
1 - 10 of 11
- Insights in febrile neutropenia (SAFE study) and clinical and translational insights in (invasive) mold infections and mycology, with the focus on Hematologic patients.From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimization and validation of collateral sensitivity based alternative treatment strategies for multidrug resistant CandidemiaFrom1 Oct 2022 → TodayFunding: IOF - technology validation in lab
- SAFE study: a randomized non-inferiority trialFrom1 Oct 2022 → TodayFunding: Foundations, funds and other with scientific goal
- Improving prevention and treatment strategies concerning opportunistic infections in immunocompromised hematologic patientsFrom14 Sep 2020 → TodayFunding: Foundations, funds and other with scientific goal
- Clonal evolution and biology of co-operative oncogenic events in acute lymphoblastic leukemia.From1 Oct 2018 → 30 Sep 2023Funding: Fund Recuperation Fiscal Exemption
- Fast diagnosis of opportunistic respiratory infections trough exhaled breath analysisFrom1 Oct 2017 → 30 Sep 2020Funding: FWO Applied Biomedical Research (TBM)
- Triazole-resistance in Aspergillus fumigatus: evolving epidemiology and influence on disease progression.From15 Mar 2017 → 2 Dec 2021Funding: BOF - doctoral mandates, BOF - Doctoral projects
- Faster to the fungus: rapid diagnostic and prognostic tests for invasive fungal diseasesFrom1 Aug 2016 → 9 Oct 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
- Rethinking 'Care after Cure' in allogeneic hematopoietic stem cell transplantation using e-Health and patient reported outcomesFrom1 Sep 2015 → 14 Nov 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Assessment of the impact of emerging azole resistance mechanisms on treatment response of invasive pulmonary aspergillosis using non-invasive imaging in experimental Aspergillus infection models.From1 Jan 2015 → 31 Dec 2018Funding: FWO research project (including WEAVE projects)
Publications
431 - 440 of 536
- Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic stem cell transplantation
Authors: Johan Maertens
Pages: 60 - 61 - Impact of ATG use on the outcome of patients with hematological malignancies undergoing reduced-intensity conditioning for allogeneic hematopoietic cell transplantation
Authors: H Greinix, E Beohou, S van der Werf, D Niederwieser, D Blaise, P Dreger, R Arnold, E Meijer, H Sengeloev, J Cornelissen, et al.
Pages: S61 - S61 - Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients-authors' response
Authors: Catherine Cordonnier, Alexandre Alanio, Simone Cesaro, Georg Maschmeyer, Hermann Einsele, J Peter Donnelly, Philippe M Hauser, Willem JG Melchers, Jannik Helweg-Larsen, Olga Matos, et al.
Pages: 1266 - 1268 - Haplo-identical transplantation (haplo-HSCT) in patients with myelodysplastic syndrome (MDS): a report from the European Society of Blood and Marrow Transplantation
Authors: M Robin, R Porcher, L Koster, F Ciceri, MT van Lint, P Di Bartolomeo, G Ehninger, D Blaise, Z Gullbas, SG Muniz, et al.
Pages: S96 - S97 - A patient with splenomegaly pancytopenia and hypergammaglobulinemia
Authors: Hélène Schoemans, Daan Dierickx, Michel Delforge, Ann Janssens, Johan Maertens, Marc Boogaerts, Gregor Verhoef, Timothy Devos
Pages: 1 - 1 - Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)
Authors: Johan Maertens
Pages: 1215 - 1226 - Allogeneic Transplantation for Acute Myeloid Leukemia with Monosomy 7 or Deletion 7q: a Study from the Acute Leukemia Working Party (ALWP) of the EBMT
Authors: Xavier Poire, Myriam Labopin, Emmanuelle Polge, Liisa Volin, Jurgen Finke, Arnold Ganser, Didier Blaise, Ibrahim Yakoub-Agha, Dietrich Beelen, Noel Milpied, et al.
Pages: 149 - 150 - Reply to Rijnders and Slobbe and to Donnelly and Leeflang
Authors: Johan Maertens
Pages: 1071 - 1073 - Prophylactic or preemptive therapy with Sorafenib after allogeneic hematopoietic cell transplantation improves overall survival of FLT3 AML patients
Authors: Ali Bazarbachi, Myriam Labopin, Giorgia Battipaglia, Azedine Djabali, Edouard Forcade, William Arcese, Gerard Socie, Didier Blaise, Jakob Passweg, Jan J Cornelissen, et al.
Pages: 109 - 110 - Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry
Authors: Johan Maertens